872 related articles for article (PubMed ID: 9718378)
21. Combined analysis of minimal residual disease at two time points and its value for risk stratification in childhood B-lineage acute lymphoblastic leukemia.
Cui L; Li Z; Wu M; Li W; Gao C; Deng G
Leuk Res; 2010 Oct; 34(10):1314-9. PubMed ID: 20034668
[TBL] [Abstract][Full Text] [Related]
22. Use of oligonucleotide probes directed against T cell antigen receptor gamma delta variable-(diversity)-joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias.
Macintyre EA; d'Auriol L; Duparc N; Leverger G; Galibert F; Sigaux F
J Clin Invest; 1990 Dec; 86(6):2125-35. PubMed ID: 2174915
[TBL] [Abstract][Full Text] [Related]
23. Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes.
Botsonis T; Tsangaris GT; Mikraki V; Tzortzatou-Stathopoulou F
Anticancer Res; 1999; 19(3B):2211-20. PubMed ID: 10472333
[TBL] [Abstract][Full Text] [Related]
24. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Ruano D; Diaz MA; Tutor O; Garcia-Sanchez F; Martinez P; Madero L
Haematologica; 2000 Aug; 85(8):877-8. PubMed ID: 10942942
[No Abstract] [Full Text] [Related]
25. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
[No Abstract] [Full Text] [Related]
26. Pattern of T-cell receptor delta gene rearrangement by Southern blotting and polymerase chain reaction technique in Hong Kong Chinese patients with non-T-cell hematological malignancies.
Chan DW; Liang R; Kwong YL
Hematol Oncol; 1996 Jun; 14(2):57-66. PubMed ID: 8876635
[TBL] [Abstract][Full Text] [Related]
27. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
28. [Detection of TCR gamma gene in acute lymphoblastic leukemia after remission and its clinical significance].
Liu L; Sun J; Yin H
Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):353-5. PubMed ID: 11189517
[TBL] [Abstract][Full Text] [Related]
29. Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in childhood acute lymphoblastic leukemia using a low-cost PCR strategy.
Assumpção JG; Ganazza MA; de Araújo M; Silva AS; Scrideli CA; Brandalise SR; Yunes JA
Pediatr Blood Cancer; 2010 Dec; 55(7):1278-86. PubMed ID: 20730889
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
31. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
34. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
35. IgH/TCR delta PCR oligonucleotide liquid hybridization, a fast and sensitive assay for monitoring minimal residual disease in childhood B-precursor ALL.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Jan; 9(1):216-22. PubMed ID: 7845021
[TBL] [Abstract][Full Text] [Related]
36. The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a comparative study.
Campana D; Yokota S; Coustan-Smith E; Hansen-Hagge TE; Janossy G; Bartram CR
Leukemia; 1990 Sep; 4(9):609-14. PubMed ID: 1975635
[TBL] [Abstract][Full Text] [Related]
37. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia.
Uckun FM; Kersey JH; Haake R; Weisdorf D; Nesbit ME; Ramsay NK
N Engl J Med; 1993 Oct; 329(18):1296-301. PubMed ID: 8413410
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment.
Yamada M; Wasserman R; Lange B; Reichard BA; Womer RB; Rovera G
N Engl J Med; 1990 Aug; 323(7):448-55. PubMed ID: 2095753
[TBL] [Abstract][Full Text] [Related]
39. Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.
Taylor JJ; Rowe D; Kylefjord H; Chessells J; Katz F; Proctor SJ; Middleton PG
Leukemia; 1994 Jan; 8(1):60-6. PubMed ID: 8289500
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
